Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102

BACKGROUND: ADS‐5102 (amantadine) extended release capsules (GOCOVRI™) are a treatment for dyskinesia in patients with Parkinson's disease (PD). ADS‐5102 reduced dyskinesia and OFF time in phase 3 controlled trials of up to six months. Amantadine immediate release (IR) is used for dyskinesia, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaacson, Stuart H., Fahn, Stanley, Pahwa, Rajesh, Tanner, Caroline M., Espay, Alberto J., Trenkwalder, Claudia, Adler, Charles H., Patni, Rajiv, Johnson, Reed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947645/
https://www.ncbi.nlm.nih.gov/pubmed/29780852
http://dx.doi.org/10.1002/mdc3.12595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947645/
https://www.ncbi.nlm.nih.gov/pubmed/29780852
http://dx.doi.org/10.1002/mdc3.12595

Ejemplares similares